Table 2 Detailed histopathological diagnosis of all malignant and benign non-mass enhancement lesions
Histopathology | N (%) | Mean size (mm) | Standard deviation (mm) | Range (mm) |
|---|---|---|---|---|
Non-mass enhancement lesions | 66 (100) | 40 | 25 | 5–98 |
Malignant | 39/66 (59) | 48.4 | 26 | 5–98 |
 Ductal carcinoma in situ | 4 (10) | 33.5 | 33 | 7–89 |
 Invasive ductal carcinoma | 24 (62) | 48 | 27 | 5–98 |
 Invasive lobular carcinoma | 9 (23) | 56.5 | 20 | 25–85 |
 IDC + DCIS | 1 (2.5) | 30 | – | – |
 IDC + LCIS | 1 (2.5) | 60 | – | – |
Benign | 27/66 (41) | 28 | 18 | 5–80 |
 FA/FAH | 5 (19) | 21.5 | 11 | 10–38 |
 Adenosis, sclerosing adenosis, focal fibrosis, apocrine metaplasia, breast parenchyma, fibrocystic changes | 12 (44) | 23 | 16 | 5–50 |
 Papilloma | 1 (4) | 45 | – | – |
 High-risk (CCC with atypia, papilloma with atypia) | 2 (7) | 42 | 3 | 40–44 |
 Other (chronic abscess, gynecomastia, fat necrosis, scar tissue) | 7 (26) | 33.5 | 24 | 6–80 |